2024 |
Quantitative Evaluation by Digital Pathology of Immunohistochemical Expression of CK7, CK19, and EpCAM in Advanced Stages of NASH |
Articolo in rivista |
Vai |
2024 |
What is the benefit of prophylaxis to prevent HBV reactivation in HBsAg-negative anti-HBc-positive patients? Meta-analysis and decision curve analysis |
Articolo in rivista |
Vai |
2024 |
Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis |
Articolo in rivista |
Vai |
2024 |
A Phase 3 Trial of Seladelpar in Primary Biliary Cholangitis |
Articolo in rivista |
Vai |
2024 |
Adequate versus deep response to ursodeoxycholic acid in primary biliary cholangitis: To what extent and under what conditions is normal alkaline phosphatase level associated with complication-free survival gain? |
Articolo in rivista |
Vai |
2023 |
Depth effect on point shear wave velocity elastography: Evidence in a chronic hepatitis C patient cohort |
Articolo in rivista |
Vai |
2023 |
Hepatic encephalopathy increases the risk for mortality and hospital readmission in decompensated cirrhotic patients: a prospective multicenter study |
Articolo in rivista |
Vai |
2023 |
Predicting de-novo portal vein thrombosis after HCV eradication: A long-term competing risk analysis in the ongoing PITER cohort |
Articolo in rivista |
Vai |
2023 |
Child-Pugh Class and Not Thrombocytopenia Impacts the Risk of Complications of Endoscopic Band Ligation in Patients with Cirrhosis and High Risk Varices |
Articolo in rivista |
Vai |
2023 |
Heart rate variability is associated with disease severity and portal hypertension in cirrhosis |
Articolo in rivista |
Vai |
2023 |
The unhealthy lifestyle in primary biliary cholangitis: An enemy to fight |
Articolo in rivista |
Vai |
2023 |
Oesophageal varices predict complications in compensated advanced non-alcoholic fatty liver disease |
Articolo in rivista |
Vai |
2023 |
Inflammation and autonomic balance in cirrhosis: Association between sympathetic nervous system and osteopontin, interleukin-22, interleukin-6 and interleukin-1Ra concentrations according to portal hypertension and disease severity |
Articolo in rivista |
Vai |
2023 |
Glecaprevir/Pibrentasvir is safe and effective in Italian patients with chronic hepatitis C aged 75 years or older: A multicentre study |
Articolo in rivista |
Vai |
2023 |
Profiling the risk of hepatocellular carcinoma after long-term HCV eradication in patients with liver cirrhosis in the PITER cohort |
Articolo in rivista |
Vai |
2022 |
Primary biliary cholangitis: perception and expectation of illness |
Articolo in rivista |
Vai |
2022 |
Corrigendum to 'Baveno VII - Renewing consensus in portal hypertension' [J Hepatol (2022) 959-974] |
Nota o commento |
Vai |
2022 |
Baveno VII – Renewing consensus in portal hypertension |
Articolo in rivista |
Vai |
2022 |
Corrigendum to ‘An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs’ [J Hepatol 2021;75(3):572–581] (Journal of Hepatology (2021) 75(3) (572–581), (S0168827821003342), (10.1016/j.jhep.2021.04.055)) |
Nota o commento |
Vai |
2022 |
RESIST-HCV Criteria to Monitor Progression of Low-Risk Esophageal Varices in Patients With Compensated Cirrhosis After HCV Eradication: The SIMPLE Study: SIMPLE: Scoring Index to Monitor Progression of Low-risk Esophageal varices |
Articolo in rivista |
Vai |
2022 |
Predictors of serious adverse events and non-response in cirrhotic patients with primary biliary cholangitis treated with obeticholic acid |
Articolo in rivista |
Vai |
2022 |
Liver stiffness measurement by vibration-controlled transient elastography improves outcome prediction in primary biliary cholangitis |
Articolo in rivista |
Vai |
2022 |
Mortality after transjugular intrahepatic portosystemic shunt in older adult patients with cirrhosis: A validated prediction model |
Articolo in rivista |
Vai |
2022 |
Mer Tyrosine Kinase (MERTK) modulates liver fibrosis progression and hepatocellular carcinoma development |
Articolo in rivista |
Vai |
2021 |
Liver and cardiovascular mortality after hepatitis C virus eradication by DAA: Data from RESIST-HCV cohort |
Articolo in rivista |
Vai |
2021 |
X Chromosome Contribution to the Genetic Architecture of Primary Biliary Cholangitis. |
Articolo in rivista |
Vai |
2021 |
Long-term evolution of LI-RADS observations in HCV-related cirrhosis treated with direct-acting antivirals |
Articolo in rivista |
Vai |
2021 |
Genetic Determinants in a Critical Domain of NS5A Correlate with Hepatocellular Carcinoma in Cirrhotic Patients Infected with HCV Genotype 1b. |
Articolo in rivista |
Vai |
2021 |
Reply to: “Hepatic benefits of HCV cure: Don't forget coagulation!” |
Recensione in rivista |
Vai |
2021 |
Accuracy of Transient Elastography in Assessing Fibrosis at Diagnosis in Naïve Patients With Primary Biliary Cholangitis: A Dual Cut-Off Approach |
Articolo in rivista |
Vai |
2021 |
First-Line Immune Checkpoint Inhibitor-Based Sequential Therapies for Advanced Hepatocellular Carcinoma: Rationale for Future Trials |
Articolo in rivista |
Vai |
2021 |
Efficacy of 8 weeks elbasvir/grazoprevir regimen for naïve-genotype 1b, HCV infected patients with or without glucose abnormalities: Results of the EGG18 study |
Articolo in rivista |
Vai |
2021 |
Resistance analysis and treatment outcomes in hepatitis C virus genotype 3-infected patients within the Italian network VIRONET-C |
Articolo in rivista |
Vai |
2021 |
Clinical features and comorbidity pattern of HCV infected migrants compared to native patients in care in Italy: A real-life evaluation of the PITER cohort |
Articolo in rivista |
Vai |
2021 |
Failure on voxilaprevir, velpatasvir, sofosbuvir and efficacy of rescue therapy |
Articolo in rivista |
Vai |
2021 |
An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs. |
Articolo in rivista |
Vai |
2021 |
Refining the Baveno VI elastography criteria for the definition of compensated advanced chronic liver disease |
Articolo in rivista |
Vai |
2021 |
Real-world experience with obeticholic acid in patients with primary biliary cholangitis. |
Articolo in rivista |
Vai |
2020 |
Impact of hepatitis C virus clearance by direct-acting antiviral treatment on the incidence of major cardiovascular events: A prospective multicentre study |
Articolo in rivista |
Vai |
2020 |
Hepatitis C virus eradication by direct antiviral agents abates oxidative stress in patients with advanced liver fibrosis |
Articolo in rivista |
Vai |
2020 |
Hepatic benefits of HCV cure |
Articolo in rivista |
Vai |
2020 |
On-treatment serum albumin level can guide long-term treatment in patients with cirrhosis and uncomplicated ascites |
Articolo in rivista |
Vai |
2020 |
Metabolic comorbidities and male sex influence steatosis in chronic hepatitis C after viral eradication by direct-acting antiviral therapy (DAAs): Evaluation by the controlled attenuation parameter (CAP) |
Articolo in rivista |
Vai |
2020 |
Reduced incidence of type 2 diabetes in patients with chronic hepatitis C virus infection cleared by direct-acting antiviral therapy: A prospective study |
Articolo in rivista |
Vai |
2020 |
Towards personalized screening for hepatocellular carcinoma: Still not there |
Recensione in rivista |
Vai |
2019 |
Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data |
Articolo in rivista |
Vai |
2019 |
Add-on peginterferon alfa-2a to nucleos(t)ide analogue therapy for Caucasian patients with hepatitis B 'e' antigen-negative chronic hepatitis B genotype D. |
Articolo in rivista |
Vai |
2019 |
Daclatasvir-based regimens in HCV cirrhosis: experience from the Italian early access program. |
Articolo in rivista |
Vai |
2019 |
Direct acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients |
Abstract in atti di convegno pubblicato in rivista |
Vai |
2019 |
Resistance test guided retreatment of HCV infected patients with a previous failure to a NS5A inhibitor-containing regimen: the Italian Vironet C real life experience |
Abstract in atti di convegno pubblicato in rivista |
Vai |
2019 |
Current epidemiology of HCV in Sicily: the RESIST-HCV model |
Abstract in atti di convegno pubblicato in rivista |
Vai |
2019 |
Point-of-care HCV RNA testing in the setting of DAA therapy: HCV-FiS (HEpatitis C Virus Fingerstick Study) |
Articolo in rivista |
Vai |
2019 |
Is Transient Elastography Needed for Noninvasive Assessment of High-Risk Varices? the REAL Experience |
Articolo in rivista |
Vai |
2019 |
Aminopyrine breath test predicts liver-related events and death in HCV-related cirrhosis on SVR after DAA therapy |
Articolo in rivista |
Vai |
2019 |
Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients |
Articolo in rivista |
Vai |
2019 |
Suboptimal performance of APRI and FIB-4 in ruling out significant fibrosis and confirming cirrhosis in HIV/HCV co-infected and HCV mono-infected patients |
Articolo in rivista |
Vai |
2018 |
HBV reactivation in patients with HCV/HBV cirrhosis on treatment with direct-acting antivirals |
Articolo in rivista |
Vai |
2018 |
Frequent NS5A and multiclass resistance in almost all HCV genotypes at DAA failures: What are the chances for second-line regimens? |
Lettera |
Vai |
2018 |
Is global elimination of HCV realistic? |
Articolo in rivista |
Vai |
2018 |
Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents |
Articolo in rivista |
Vai |
2018 |
Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents |
Articolo in rivista |
Vai |
2018 |
Real life experiences in HCV management in 2018 |
Articolo in rivista |
Vai |
2018 |
Predictors of hepatocellular carcinoma in HCV cirrhotic patients treated with direct acting antivirals. |
Articolo in rivista |
Vai |
2018 |
Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial. |
Articolo in rivista |
Vai |
2018 |
High efficacy of direct-acting anti-viral agents in hepatitis C virus-infected cirrhotic patients with successfully treated hepatocellular carcinoma. |
Articolo in rivista |
Vai |
2018 |
Sofosbuvir plus daclatasvir with or without ribavirin is safe and effective for post-transplant hepatitis C recurrence and severe fibrosis and cirrhosis: A prospective study |
Articolo in rivista |
Vai |
2018 |
Predictors of Re‐bleeding and Mortality Among Patients
with Refractory Variceal Bleeding Undergoing Salvage Transjugular Intrahepatic Portosystemic Shunt (TIPS) |
Articolo in rivista |
Vai |
2018 |
The course of oesophagogastric varices in patients with cirrhosis after DAA-induced HCV clearance |
Abstract in atti di convegno pubblicato in rivista |
Vai |
2018 |
Non-invasive prediction of esophageal varices by stiffness and platelet in non-alcoholic fatty liver disease cirrhosis |
Articolo in rivista |
Vai |
2018 |
Disease outcomes after DAA-induced SVR: Data from the resist-HCV cohort |
Poster pubblicato in rivista |
Vai |
2018 |
Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis |
Articolo in rivista |
Vai |
2018 |
Corrigendum to “Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV” [J Hepatol 68 (2018) 33–41](S0168827817322596)(10.1016/j.jhep.2017.08.019) |
Nota o commento |
Vai |
2018 |
Hepatitis C Virus Eradication by Direct Antiviral Agents Improves Carotid Atherosclerosis in patients with Severe Liver Fibrosis |
Articolo in rivista |
Vai |
2017 |
Improvement of ALT decay kinetics by all-oral HCV treatment: Role of NS5A inhibitors and differences with IFN-based regimens |
Articolo in rivista |
Vai |
2017 |
HBV recurrence after HCV clearance on DAAs: Sometimes they come back |
Nota o commento |
Vai |
2017 |
Improved survival of patients with hepatocellular carcinoma and compensated hepatitis C virus-related cirrhosis who attained sustained virological response |
Articolo in rivista |
Vai |
2017 |
Hepatocellular carcinoma and direct-acting antivirals: A never ending story? |
Articolo in rivista |
Vai |
2017 |
Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV |
Articolo in rivista |
Vai |
2017 |
A focus on epidemiology of drug-induced liver injury: analysis of a prospective cohort |
Articolo in rivista |
Vai |
2017 |
Treatment of Hepatitis C virus infection in Italy: A consensus report from an expert panel |
Articolo in rivista |
Vai |
2017 |
Is early recurrence of hepatocellular carcinoma in HCV cirrhotic patients affected by treatment with direct-acting antivirals? A prospective multicentre study |
Articolo in rivista |
Vai |
2017 |
Is early recurrence of hepatocellular carcinoma in HCV cirrhotic patients affected by treatment with direct-acting antivirals? A prospective multicentre study |
Articolo in rivista |
Vai |
2017 |
Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: Interim evaluations from the PITER network |
Articolo in rivista |
Vai |
2017 |
Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies |
Articolo in rivista |
Vai |
2017 |
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study |
Articolo in rivista |
Vai |
2017 |
Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication |
Articolo in rivista |
Vai |
2016 |
Effects of Eradicating Hepatitis C Virus Infection in Patients With Cirrhosis Differ With Stage of Portal Hypertension |
Articolo in rivista |
Vai |
2016 |
Impact of virus eradication in patients with compensated hepatitis C virus-related cirrhosis: competing risks and multistate model |
Articolo in rivista |
Vai |
2016 |
Hemostatic balance in patients with liver cirrhosis: Report of a consensus conference |
Articolo in rivista |
Vai |
2016 |
AISF position paper on liver disease and pregnancy. |
Articolo in rivista |
Vai |
2016 |
Why do I treat my patients with mild hepatitis C? |
Articolo in rivista |
Vai |
2016 |
HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels |
Articolo in rivista |
Vai |
2016 |
Dual therapy with peg-interferon and ribavirin in thalassemia major patients with chronic HCV infection: Is there still an indication? |
Articolo in rivista |
Vai |
2016 |
Survival of patients with HCV cirrhosis and sustained virologic response is similar to the general population. |
Articolo in rivista |
Vai |
2016 |
AISF position paper on liver transplantation and pregnancy: Women in Hepatology Group, Italian Association for the Study of the Liver (AISF). |
Articolo in rivista |
Vai |
2016 |
Increased expression of markers of early atherosclerosis in patients with inflammatory bowel disease |
Articolo in rivista |
Vai |
2015 |
Ovarian senescence increases liver fibrosis in humans and zebrafish with steatosis |
Articolo in rivista |
Vai |
2015 |
Meccanismi immunologici e molecolari del danno epatico da farmaci |
Articolo in rivista |
Vai |
2015 |
Residual risk of hepatocellular carcinoma after HCV eradication: more than meets the eye. |
Review essay (rassegna critica) |
Vai |
2015 |
Quantification of fibrosis by collagen proportionate area predicts hepatic decompensation in hepatitis C cirrhosis |
Articolo in rivista |
Vai |
2015 |
Comparison of Histochemical Staining Methods and Correlation with Transient Elastography in Acute Hepatitis. |
Articolo in rivista |
Vai |
2015 |
Undetectable HCV-RNA at treatment-week 8 results in high-sustained virological response in HCV G1 treatment-experienced patients with advanced liver disease: The International Italian/Spanish Boceprevir/Peginterferon/Ribavirin Name Patients Program |
Articolo in rivista |
Vai |
2015 |
Comparison of Histochemical Stainings in Evaluation of Liver Fibrosis and Correlation with Transient Elastography in Chronic Hepatitis |
Articolo in rivista |
Vai |
2014 |
Clinical implications of the hyperdynamic syndrome in cirrhosis. |
Articolo in rivista |
Vai |
2014 |
Identification of naïve HCV-1 patients with chronic hepatitis who may benefit from dual therapy with peg-interferon and ribavirin |
Articolo in rivista |
Vai |
2014 |
Regression of fibrosis after HBV antiviral therapy. Is cirrhosis reversible? |
Articolo in rivista |
Vai |
2014 |
The risk of hepatocellular carcinoma in HBV cirrhosis is affected by polymorphisms of the MERTK gene |
Abstract in rivista |
Vai |
2014 |
Performance of two HCV RNA assays during protease inhibitor-based triple therapy in patients with advanced liver fibrosis and cirrhosis. |
Articolo in rivista |
Vai |
2014 |
An a priori prediction model of response to peginterferon plus ribavirin dual therapy in naïve patients with genotype 1 chronic hepatitis C |
Articolo in rivista |
Vai |
2013 |
NT pro BNP plasma level and atrial volume are linked to the severity of liver cirrhosis. |
Articolo in rivista |
Vai |
2013 |
Immunological alterations in hepatitis C virus infection |
Articolo in rivista |
Vai |
2013 |
Randomised study comparing 48 and 96 weeks peginterferon α-2a therapy in genotype D HBeAg-negative chronic hepatitis B |
Articolo in rivista |
Vai |
2013 |
Digital image analysis of collagen assessment of progression of fibrosis in
recurrent HCV after liver transplantation |
Articolo in rivista |
Vai |
2013 |
Modified spleen stiffness measurement by transient elastography is associated with presence of large oesophageal
varices in patients with compensated hepatitis C virus cirrhosis |
Articolo in rivista |
Vai |
2013 |
MECCANISMI IMMUNOLOGICI E MOLECOLARI DEL DANNO EPATICO DA FARMACI |
Proceedings |
Vai |
2013 |
Role of IL-28B and inosine triphosphatase polymorphisms in efficacy and safety of Peg-Interferon and ribavirin in chronic hepatitis C compensated cirrhosis with and without oesophageal varices. |
Articolo in rivista |
Vai |
2013 |
HBsAg quantification in HBeAg negative cirrhosis on nucleoside/nucleotide analogue (NA) and risk of development of HCC |
Abstract in rivista |
Vai |
2013 |
A rs4374383 Single Nucleotide Polymorphisms of MERTK gene is linked to a higher likelihood of hepatocellular carcinoma in patients with HCV cirrhosis |
Abstract in rivista |
Vai |
2013 |
Who is more likely to respond to dual treatment with pegylated-interferon and ribavirin for chronic hepatitis C? A gender-oriented analysis. |
Articolo in rivista |
Vai |
2013 |
Fibrosis Evaluation by Transient Elastography in Patients With Long-Term Sustained HCV Clearance |
Articolo in rivista |
Vai |
2012 |
The
relationship between transient elastography and histological collagen
proportionate area for assessing fibrosis in chronic viral hepatitis |
Articolo in rivista |
Vai |
2012 |
Liver collagen proportionate area predicts decompensation in patients with recurrent hepatitis C virus cirrhosis after liver transplantation |
Articolo in rivista |
Vai |
2012 |
Fecal calprotectin in clinical practice: a noninvasive screening tool for patients with chronic diarrhea |
Articolo in rivista |
Vai |
2012 |
Risk of disease decompensation and HCC in patients with HCV cirrhosis non responders to PEG IFN plus RBV |
Abstract in rivista |
Vai |
2012 |
IL28B polymorphisms influence stage of fibrosis and
spontaneous or interferon-induced viral clearance in thalassemia patients with
hepatitis C virus infection. |
Articolo in rivista |
Vai |
2011 |
Serum ferritin is a discriminant marker for both fibrosis and inflammation in histologically proven non-alcoholic fatty liver disease patients |
Articolo in rivista |
Vai |
2011 |
COMPUTER ASSISTED IMAGE ANALYSIS OF LIVER COLLAGEN: RELATIONSHIP TO ESOPHAGEAL VARICES, LIVER DECOMPENSATION AND SVR IN PATIENTS WITH COMPENSATED HCV CIRRHOSIS |
Tesi di dottorato pre 2013 |
Vai |
2011 |
Liver stiffness measurement by transient elastography predicts early recovery from acute hepatitis |
Recensione in rivista |
Vai |
2011 |
Comparison of transient elastography and acoustic radiation force impulse for non-invasive staging of liver fibrosis in patients with chronic hepatitis C. |
Articolo in rivista |
Vai |
2011 |
Comparison of cystatin C and creatinine-based glomerular filtration
rate formulas with 51Cr-EDTA clearance in patients with cirrhosis |
Articolo in rivista |
Vai |
2011 |
Digital image analysis of liver collagen predicts clinical
outcome of recurrent hepatitis C virus 1 year after liver transplantation. |
Articolo in rivista |
Vai |
2011 |
PEG-INTERFERON PLUS RIBAVIRIN IN HCV CIRRHOSIS WITH PORTAL HYPERTENSION: ROLE OF VIRAL AND HOST FACTORS IN HCV CLEARANCE |
Abstract in rivista |
Vai |
2011 |
LIVER RELATED EVENTS AND SURVIVAL IN PATIENTS WITH COMPENSATED HCV CIRRHOSIS: THE ROLE OF SUSTAINED VIROLOGICAL RESPONSE TO PEG-IFN BASED THERAPY AND PORTAL HYPERTENSION |
Abstract in rivista |
Vai |
2011 |
Pegylated-interferon-α(2a) in clinical
practice: how to manage patients suffering from side effects |
Articolo in rivista |
Vai |
2011 |
Fibrosis in chronic viral hepatitis |
Articolo in rivista |
Vai |
2010 |
Clinical course and outcomes of drug-induced liver injury: Nimesulide as the first implicated medication. |
Articolo in rivista |
Vai |
2010 |
Hepassocin as a treatment for fulminant hepatic failure: will it
translate from rats to human? |
Recensione in rivista |
Vai |
2010 |
Histological subclassification of cirrhosis |
Recensione in rivista |
Vai |
2010 |
Critically ill patients with cirrhosis and low serum sodium. |
Articolo in rivista |
Vai |
2010 |
Enhanced thrombin generation in patients with cirrhosis-induced coagulopathy |
Articolo in rivista |
Vai |
2009 |
Noninvasive assessment of liver fibrosis in thalassaemia major patients by transient elastography (TE) - lack of interference by iron deposition. |
Articolo in rivista |
Vai |
2009 |
Impact of Tips Preliver Transplantation
for the Outcome Posttransplantation |
Articolo in rivista |
Vai |
2009 |
RIFLE classification as predictive factor of mortality in patients with cirrhosis admitted to intensive care unit. |
Articolo in rivista |
Vai |
2009 |
PEG_interferon plus Ribavirin in compensated HCV cirrhosis with portal hypertension: the role of rapid and early virological response in predicting the sustained virological response |
Proceedings |
Vai |
2009 |
Fibrosis staging in chronic hepatitis C: analysis of discordance between transient elastography and liver biopsy |
Articolo in rivista |
Vai |
2009 |
A simple, noninvasive test for the diagnosis of liver fibrosis in patients with hepatitis C recurrence after liver transplantation. |
Articolo in rivista |
Vai |
2009 |
PEG-interferon plus Ribavirin in compensated HCV cirrhosis with portal hypertension: the role of rapid and early virological response in predicting the sustained virological response |
Proceedings |
Vai |
2009 |
Insulin resistance is a major determinant of liver stiffness in nondiabetic patients with HCV genotype 1 chronic hepatitis |
Articolo in rivista |
Vai |
2009 |
An evaluation of transient elastography in the discrimination of HBeAg-negative disease from inactive hepatitis B carriers |
Articolo in rivista |
Vai |
2009 |
Prospective comparison of Fibroscan, King's score and liver biopsy for the assessment of cirrhosis in chronic hepatitis C infection. |
Articolo in rivista |
Vai |
2009 |
Computer-Assisted Image Analysis of Liver Collagen:
Relationship to Ishak Scoring and Hepatic Venous
Pressure Gradient |
Articolo in rivista |
Vai |
2009 |
PEG-INTERFERON PLUS RIBAVIRIN IN COMPENSATED HCV CIRRHOSIS WITH PORTAL HYPERTENSION: THE ROLE OF RAPID AND EARLY VIROLOGICAL RESPONSE IN PREDICTING THE SUSTAINED VIROLOGICAL RESPONSE |
Abstract in rivista |
Vai |
2009 |
HCV CLEARANCE AFTER PEG IFN PLUS RBV IMPROVES THE COURSE OF HCV CIRRHOSIS REGARDLESS OF PORTAL HYPERTENSION |
Abstract in rivista |
Vai |
2009 |
Implication of Normal Liver Enzymes in Liver Disease |
Articolo in rivista |
Vai |
2008 |
TACE versus TAE as therapy for hepatocellular carcinoma. |
Articolo in rivista |
Vai |
2008 |
Coagulation and fibrosis in chronic liver disease. |
Articolo in rivista |
Vai |
2008 |
Muscle cramps in cirrhosis: the therapeutic value of quinine. Is it underused? |
Articolo in rivista |
Vai |
2008 |
Models for non-alcoholic fatty liver disease: a link with vascular risk. |
Articolo in rivista |
Vai |
2008 |
CLINICAL COURSE OF NIMESULIDE-INDUCED LIVER INJURY |
Proceedings |
Vai |
2008 |
Pegylated-interferon and ribavirin in liver transplant candidates and recipients with HCV cirrhosis: systematic review and meta-analysis of prospective controlled studies. |
Articolo in rivista |
Vai |
2007 |
The impact of sustained virological response on clinical outcomes in compensated HCV cirrhosis: a prospective cohort study |
Proceedings |
Vai |
2007 |
Peg-interferon alone or combined with ribavirin in HCV cirrhosis with portal hypertension:a randomized controlled trial |
Articolo in rivista |
Vai |
2007 |
The impact of sustained virological response on clinical outcome in compensated HCV cirrhosis: a prospective cohort study |
Proceedings |
Vai |
2006 |
Different doses of consensus interferon plus ribavirin in patients with hepatitis C virus genotype 1 relapsed after interferon monotherapy: a randomized controlled trial |
Articolo in rivista |
Vai |
2006 |
The effect of antiviral therapy on clinical outcome of HCV cirrhosis with portal hypertension: a prospective cohort study. |
Articolo in rivista |
Vai |
2006 |
High rate of spontaneous viral clearance in patients with iatrogenic acute hepatitis C |
Articolo in rivista |
Vai |